Skip to content

Needing Dicang (ST 4) through Jiache (ST 6) on tumor after chemotherapy- induced oral mucositis

Needing Dicang (ST 4) through Jiache (ST 6) on tumor after chemotherapy curative effect observation of oral mucositis

Status
Recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2300073038
Enrollment
Unknown
Registered
2023-06-30
Start date
2023-06-20
Completion date
Unknown
Last updated
2023-07-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

The tumor after chemotherapy oral mucositis

Interventions

Treatment group:Needing Dicang (ST 4) through Jiache (ST 6) +Kangfuxin Ye
Control group:Kangfuxin Ye

Sponsors

Shanghai Putuo District Central Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
30 Years to 70 Years

Inclusion criteria

Inclusion criteria: (1) volunteered for this study, and signed informed consent; (2) there is a clear pathological diagnosis of tumors, accept standard of adjuvant chemotherapy, expected lifetime > 3 months; (3) in tumor chemotherapy oral mucositis of Chinese and western medicine diagnostic criteria, and oral mucositis class 2 and above, the course < 3 months; (4) 3 days before the onset and the incidence after not taking other drugs or related treatment; (5) normal mental, no facial paralysis and facial paralysis facial diseases; (6) age between 30 ~ 70 years old (or female).

Exclusion criteria

Exclusion criteria: (1) does not comply with the above conditions; (2) the combination of white's disease, recurrent oral ulcer, tuberculous oral ulcer and herpetic stomatitis, etc., and can't clear for patients with oral cavity mucositis caused by chemotherapy; (3) merging and heart, liver, renal insufficiency, metabolic disease, hemorrhagic disease, severe infections, immune function is not complete, mental illness, mental illness, etc.; (4) easy to treatment, can't insist on acupuncture therapy; (5) the pregnant women, nursing mothers, and blood coagulation function disorder;

Design outcomes

Secondary

MeasureTime frame
Cellular inflammatory factor;C-reactive protein;CD series immune indexes;

Primary

MeasureTime frame
Oral cavity mucous membrane of sex of chemotherapy evaluation questionnaire;faces pain scale-Revised,FPS-R;The average ulcer stage;

Countries

Chins

Contacts

Public ContactZuo Qingsong

Shanghai Putuo District Central Hospital

Zqsadsl123@163.com+86 139 1805 3349

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026